Mechanisms Associated with Unusual Orofacial Pain

This article presents an overview of possible mechanisms associ-ated with pain perception, with a specific focus on understanding unusual manifestations of orofacial pain associated with nerve insult. It includes recent evidence concerning neurobiological changes that occur in the periphery at tissue and nerve sites, or within the central nervous system, and that may involve chemical and inflammatory responses, sensitization, or alterations of cellu-lar function. Moreover, the contribution of the autonomic nervous system, changes in emotional reactivity and vigilance, the roles of high brain centers such as the basal ganglia (nigro-striatal) system, and the influence of aging and gender, are briefly described.

chronic pain; nerve damage; orofacial pain; pain; pain perception; nervous system

1. Zakrzewska JM, Hamlyn PJ. Facial pain. In: International Association for the Study of Pain. Task Force on Epidemiology. Epidemiology of Pain. Seattle: IASP Press, 1999:171–202.

2. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389–400.

3. Brown RS, Arm RN, Sirois D. Clinician’s Guide to the Diagnosis and Treatment of Chronic Orofacial Pain. Baltimore: American Academy of Oral Medicine, 1999.

4. Kitt CA, Gruber K, Davis M, Woolf CJ, Levine JD. Trigeminal neuralgia: Opportunities for research and treatment. Pain 2000;85:3–7.

5. Göbel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001;91:195–199.

6. Holland GR. Management of dental pain. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:211–220.

7. Truelove E. Management of mucosal pain. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:249–258.

8. Turner JA, Dworkin SF, Mancl L, Huggins KH, Truelove EL. The roles of beliefs, catastrophizing, and coping in the functioning of patients with temporomandibular disor-ders. Pain 2001;92:41–51.

9. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000;288:1769–1772.

10. Miloro M, Halkias LE, Mallery S, Travers S, Rashid RG. Low-level laser effect on neural regeneration in Gore-Tex tubes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:27–34.

11. Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: A review. J Am Dent Assoc 2000;131:184–195.

12. Siegel MA, Silverman S Jr, Sollecito TP. Clinician’s Guide to Treatment of Common Oral Conditions. Baltimore: American Academy of Oral Medicine, 2001.

13. Dworkin SF, Huggins KH, Wilson L, et al. A randomized clinical trial using research diagnostic criteria for temporo-mandibular disorders-Axis II to target clinic cases for a tailored self-care TMD treatment program. J Orofac Pain 2002;16:48–63.

14. Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self–care for the treatment of jaw pain upon awakening: A randomized clinical trial. J Orofac Pain 2002;16:64–79.

15. Goulet J-P. Temporomandibular disorders. In: Rakel RE, Bope ET (eds). Conn’s Current Therapy. Philadelphia: Saunders, 2002:94–1002.

16. Woolf CJ, Mannion RJ. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959–1964.

17. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: A randomised placebo-controlled study. Pain 2004;108:51–57.

18. Zakrzewska JM (ed). Assessment and management of oro-facial pain—Pain research and clinical management. Amsterdam: Elsevier, 2002.

19. Truelove E. Management issues of neuropathic trigeminal pain from a dental perspective. J Orofac Pain 2004;18: 374–380.

20. International Association for the Study of Pain. Classification of chronic pain. Seattle: IASP Press, 1994.

21. American Academy of Orofacial Pain. Okeson JP (ed). Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management. Chicago: Quintessence, 1996.

22. Bromm B. Consciousness, pain, and cortical activity. In: Bromm B, Desmedt JE (eds). Pain and the Brain: From Nociception to Cognition. New York: Raven Press, 1995:35–59.

23. McNeill C. What is pain and how do we classify orofacial pain? In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:3–14.

24. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;3: 153–162.

25. Witter J, Simon LS, Dionne R. Are means meaningless?The application of individual responder analysis to analgesic drug development. APS Bulletin 2003;13(6):1, 5.

26. Feinmann C, Newton-John T. Psychiatric and psychological management considerations associated with nerve damage and neuropathic trigeminal pain. J Orofac Pain 2004;18:360–365.

27. Dworkin SF. Psychosocial issues. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:115–127.

28. Woda A. Mechanisms of neuropathic pain. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:67–78.

29. Woda A, Pionchon P. A unified concept of idiopathic orofacial pain: Pathophysiologic features. J Orofac Pain 2000;14:196–212.

30. Hargreaves KM. Neurochemical factors in injury and inflammation of orofacial tissues. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:59–66.

31. Costigan M, Woolf CJ. Pain: Molecular mechanisms. J Pain 2000;1:35–44.

32. Sessle BJ, Iwata K. Central nociceptive pathways. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:47–58.

33. Sessle BJ. Acute and chronic craniofacial pain: Brainstem mechanisms of nociceptive transmission and neuroplasticity, and their clinical correlates. Crit Rev Oral Biol Med 2000;11:57–91.

34. Woda A. Pain in the trigeminal system: From orofacial nociception to neural network modeling. J Dent Res 2003; 82:764–768.

35. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH. Superficial NK-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 2002;5:1319–1326.

36. Basbaum AI, Jessell TM. The perception of pain. In: Kandel ER, Schwartz JH, Jessell TM (eds). Principles of Neural Science. New York: McGraw-Hill, 2000:472–491.

37. Bushnell MC. Perception and behavioral modulation of pain. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:107–114.

38. Maixner W. Pain modulatory systems. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ. Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:79–94.

39. Melzack R, Wall PD. Pain mechanisms: A new theory. Science 1965;150:971–979.

40. Willer JC, Roby A, Le Bars D. Psychophysical and electrophysiological approaches to the pain-relieving effects of heterotopic nociceptive stimuli. Brain 1984;107: 1095–1112.

41. Le Bars D, Willer JC, De Broucker T. Morphine blocks descending pain inhibitory controls in humans. Pain 1992;48:13–20.

42. Willer JC, Le Bars D. Electrophysiologic studies of morphine analgesia in humans. In: Bromm B, Desmedt JE (eds). Pain and the Brain: From Nociception to Cognition. New York: Raven Press, 1995:541–557.

43. Reinert A, Treede R-D, Bromm B. The pain inhibiting pain effect: An electrophysiological study in humans. Brain Res 2000;862:103–110.

44. Winston J, Toma H, Shenoy M, Pasricha PJ. Nerve growth factor regulates VR-1 mRNA levels in cultures of adult dorsal root ganglion neurons. Pain 2001;89: 181–186.

45. Malcangio M, Lessmann V. A common thread for pain and memory synapses? Brain-derived neurotrophic factor and trkB receptors. Trends Pharmacol Sci 2003;24: 116–121.

46. Bhave G, Hu HJ, Glauner KS, et al. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S A 2003;100:12480–12485.

47. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765–1769.

48. Ruocco I, Cuello AC, Ribeiro-Da-Silva A. Peripheral nerve injury leads to the establishment of a novel pattern of sympathetic fibre innervation in the rat skin. J Comp Neurol 2000;422:287–296.

49. Danziger N, Gautron M, Le Bars D, Bouhassira D. Activation of diffuse noxious inhibitory controls (DNIC) in rats with an experimental peripheral mononeuropathy. Pain 2001;91:287–296.

50. Xu X-J, Plesan A, Yu W, Hao J-X, Wiesenfeld-Hallin Z. Possible impact of genetic differences on the development of neuropathic pain-like behaviors after unilateral sciatic nerve ischemic injury in rats. Pain 2001;89:135–145.

51. Byers MR, Narhi MV. Dental injury models: Experi-mental tools for understanding neuroinflammatory interactions and polymodal mociceptor functions. Crit Rev Oral Biol Med 1999;10:4–39.

52. Fried K, Bongenhielm U, Boissonade FM, Robinson PP. Nerve injury-induced pain in the trigeminal system. Neuroscientist 2001;7:155–165.

53. Robinson PP, Boissonade FM, Loescher AR, et al. Peripheral mechanisms for the initiation of pain following trigeminal nerve injury. J Orofac Pain 2004;18:287–292.

54. Ramien M, Ruocco I, Cuello AC, St-Louis M, Ribeiro-Da-Silva A. Parasympathetic nerve fibers invade the upper dermis following sensory denervation of the rat lower lip skin. J Comp Neurol 2004;469:83–95.

55. Bereiter DA, Bereiter DF. Morphine and NMDA receptor antagonism reduce c-fos expression in spinal trigeminal nucleus produced by acute injury to the TMJ region. Pain 2000;85:65–77.

56. Cairns BE, Sessle BJ, Hu JW. Characteristics of glutamate-evoked temporomandibular joint afferent activity in the rat. J Neurophysiol 2001;85:2446–2454.

57. Dubner R, Ren K. Brainstem mechanisms of persistent pain following injury. J Orofac Pain 2004;18:299–305.

58. Eide PK, Rabben T. Trigeminal neuropathic pain: Pathophysiological mechanisms examined by quantitative assessment of abnormal pain and sensory perception. Neurosurgery 1998;43:1103–1110.

59. Iwata K, Tsuboi Y, Shima A, et al. Central neuronal changes after nerve injury: Neuroplastic influences of injury and aging. J Orofac Pain 2004;18:293–298.

60. Bradbury EJ, McMahon SB, Ramer MS. Keeping in touch: Sensory neurone regeneration in the CNS. Trends Pharmacol Sci 2000;21:389–394.

61. Wong ST, Henley JR, Kanning KC, Huang K-H, Bothwell M, Poo M-M. A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glyco-protein. Nat Neurosci 2002;5:1302–1308.

62. Wang KC, Koprivica V, Kim JA, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002;417:941–944.

63. Salter MW. Cellular neuroplasticity mechanisms mediating pain resistance. J Orofac Pain 2004;18:318–324.

64. Hu B, Chiang CY, Hu JW, Dostrovsky JO, Sessle BJ. P2X receptors in trigeminal subnucleus candalis modulate central sensitization in trigeminal subnucleus oralis. J Neurophysiol 2002;88:1614–1624.

65. Watkins LR, Milligan ED, Maier SF. Glial activation: A driving force for pathological pain. Trend Neurosci 2001;24:450–455.

66. Jordt SE, Bautista DM, Chuang HH, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004;427:260–265.

67. Dray A. Future pharmacologic management of neuropathic pain. J Orofac Pain 2004;18:381–385.

68. van Gool AV, Ten Bosch JJ, Boering G. Clinical conse-quences of complaints and complications after removal of the mandibular third molar. Int J Oral Surg 1977;6: 29–37.

69. Kipp DP, Golsdtein BH, Weiss WW Jr. Dysesthesia after mandibular third molar surgery: A retrospective study and analysis of 1,377 surgical procedures. J Am Dent Assoc 1980;100:185–192.

70. Labanc JP, Gregg JM. Trigeminal nerve injuries. Basic problems, historical perspectives, early successes, and remaining challenges. Oral Maxillofac Surg Clin North Am 1992;2:277–283.

71. Smith AC, Barry SE, Chiong AY, et al. Inferior alveolar nerve damage following removal of mandibular third molar teeth. A prospective study using panoramic radiography. Aust Dent J 1997;42:149–152.

72. Simpson HE. Injuries to the inferior dental and mental nerves. J Oral Surg Anesth Hosp Dent Serv 1958;16: 300–305.

73. Sandor GK, Stoelinga PJ, Tideman H. Reappraisal of the mandibular step osteotomy. J Oral Maxillofac Surg 1982;40:78–91.

74. de Koomen HA. A prosthetic view on vestibuloplasty with free mucosal graft. Int J Oral Surg 1977;6:38–41.

75. Bailey PH, Bays RA. Evaluation of long–term sensory changes following mandibular augmentation procedures. J Oral Maxillofac Surg 1984;42:722–727.

76. Campbell RL, Shamaskin RG, Harkins SW. Assessment of recovery from injury to inferior alveolar and mental nerves. Oral Surg Oral Med Oral Pathol 1987;64: 519–526.

77. Robinson PP, Smith KG. Lingual nerve damage during lower third molar removal: A comparison of two surgical methods. Br Dent J 1996;180:456–461.

78. Berge TI. Incidence of chronic neuropathic pain subsequent to surgical removal of impacted third molars. Acta Odontol Scand 2002;60:108–112.

79. Valmaseda-Castellon E, Berini-Aytés L, Gay-Escoda C. Inferior alveolar nerve damage after lower third molar surgical extraction: A prospective study of 1117 surgical extractions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:377–383.

80. Ylikontiola L, Kinnunen J, Laukkanen P, Oikarinen K. Prediction of recovery from neurosensory deficit after bilateral sagittal split osteotomy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:275–281.

81. Renton TF, Thexton A, Hankins M, McGurk M. Quantitative thermosensory testing of the lingual and inferior alveolar nerves, in health after iatrogenic injury. Br J Oral Maxillofac Surg 2003;41:36–42.

82. Eliav E, Gracely RH, Nahlieli O, Benoliel R. Quantitative sensory testing in trigeminal nerve damage assessment. J Orofac Pain 2004;18:339–344.

83. Essick GK. Psychological assessment of patients with post-traumatic neuropathic trigeminal pain. J Orofac Pain 2004;18:345–354.

84. Svensson P, Baad-Hansen L, Thygesen T, Juhl GI, Jensen TS. Overview on tools and methods to assess neuropathic trigeminal pain. J Orofac Pain 2004;18:332–338.

85. Imamura Y, Shiiba S, Sakamoto E, Masumi S, Nakanishi O. Predicting prognosis of abnormal sensation after trigeminal nerve injury. APS Bulletin 2002;12(3):3–10.

86. Jääskeläinen SK. The utility of clinical neurophysiological and quantitative sensory testing for trigeminal neuropathy. J Orofac Pain 2004;18:355–359.

87. Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain 2002;99: 41–47.

88. Ship JA, Grushka M, Lipton JA, Mott AE, Sessle BJ, Dionne RA. Burning mouth syndrome: An update. J Am Dent Assoc 1995;126:842–853.

89. Pedersen AML, Smidt D, Nauntofte B, Christiani CJ, Jerlang BB. Burning mouth syndrome: Etiopathogenic mechanisms, symptomatology, diagnosis and therapeutic approaches. Oral Biosci Med 2004;1:3–19.

90. Nagler RM, Hershkovich O. Sialochemical and gustatory analysis in patients with oral sensory complaints. J Pain 2004;5:56–63.

91. Jääskeläinen SK, Rinne JO, Forssell H, et al. Role of the dopaminergic system in chronic pain—A fluorodopa-PET study. Pain 2001;90:257–260.

92. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D(1) and D(2) receptors in burning mouth syndrome. Pain 2003;101:149–154.

93. Grushka M, Bartoshuk LM. Burning mouth syndrome and oral sysesthesias. Oral Health 2001;91:27–33.

94. Jerlang BB. Burning mouth syndrome (BMS) and the con-cept of alexithymia—A preliminary study. J Oral Pathol Med 1997;26:249–253.

95. Nyklicek I, Vingerhoets AJJM. Alexithymia is associated with low tolerance to experimental painful stimulation. Pain 2000;85:471–475.

96. Bazydlo R, Lumley MA, Roehrs T. Alexithymia and polysomnographic measures of sleep in healthy adults. Psychosom Med 2001;63:56–61.

97. Heckmann SM, Heckmann JG, Hilz MJ, et al. Oral mucosal blood flow in patients with burning mouth syndrome. Pain 2001;90:281–286.

98. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome and other oral sensory disorders: A unifying hypothesis. Pain Res Manage 2003;8:133–135.

99. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997;13: 189–196.

100. Dao TTT, Reynolds WJ, Tenenbaum HC. Comorbidity between myofascial pain of the masticatory muscles and fibromyalgia. J Orofac Pain 1997;11:232–241.

101. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyal-gia patients and healthy subjects. Pain 1997;70:41–51.

102. Staud R, Robinson ME, Vierck CJ Jr, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 2003;101: 167–174.

103. Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420–1429.

104. Cohen H, Neumann L, Alhosshle A, Kotler M, Abu-Shakra M, Buskila D. Abnormal sympathovagal balance in men with fibromyalgia. J Rheumatol 2001;28: 581–589.

105. Martinez-Lavin M, Hermosillo AG, Rosas M, Soto M-E. Circadian studies of autonomic nervous balances in patients with fibromyalgia: A heart rate variability analysis. Arthritis Rheum 1998;41:1966–1971.

106. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997;40:1928–1939.

107. Drewes AM. Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis. Rheumatology (Oxford) 1999;38:1035–1044.

108. Lavigne GJ, Brousseau M, Montplaisir J, Mayer P. Pain and sleep disturbances. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001: 139–150.

109. Starkstein SE, Preziosi TJ, Robinson RG. Sleep disorders, pain, and depression in Parkinson’s disease. Eur Neurol 1991;31:352–355.

110. Weiner WJ, Lang AE. Movement Disorders: A Comprehensive Study. New York: Futura Publis, 1989.

111. Jankovic J, Tolosa E. Facial Dyskinesias. Advances in Neurology. New York: Raven Press, 1988.

112. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995;60:3–38.

113. Chudler EH. Response properties of neurons in the caudate-putamen and globus pallidus to noxious and non-noxious thermal stimulation in anesthetized rats. Brain Res 1998;812:283–288.

114. Magnusson JE, Fisher K. The involvement of dopamine in nociception: The role of D1 and D2 receptors in the dorsolateral striatum. Brain Res 2000;855:260–266.

115. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38: 926–938.

116. Bennett RM. Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999;74:385–398.

117. Novak JC, Lovell JA, Stuesse SL, Cruce WLR, McBurney DL, Crisp T. Aging and neuropathic pain. Brain Res 1999;833:308–310.

118. Washington LL, Gibson SJ, Helme RD. Age-related differences in the endogenous analgesic response to repeated cold water immersion in human volunteers. Pain 2000; 89:89–96.

119. Wright GE, Parker JC, Smarr KL, Johnson JC, Hewett JE, Walker SE. Age, depressive symptoms, and rheumatoid arthritis. Arthritis Rheum 1998;41:298–305.

120. Gibson SJ, Helme RD. Cognitive factors and the experience of pain and suffering in older persons. Pain 2000;85: 375–383.

121. Riley JL, Wade JB, Robinson ME, Price DD. The stages of pain processing across the adult lifespan. J Pain 2000;1:162–170.

122. Riley JL III, Gilbert GH. Orofacial pain symptoms: An interaction between age and sex. Pain 2001;90:245–256.

123. Watkins KW, Shifren K, Park DC, Morrell RW. Age, pain, and coping with rheumatoid arthritis. Pain 1999;82:217–228.

124. Harkins SW, Price DD, Martelli M. Effects of age on pain perception: Thermonociception. J Gerontol 1986;41: 58–63.

125. Meh D, Denislic M. Quantitative assessment of thermal and pain sensitivity. J Neurol Sci 1994;127:164–169.

126. Englert S, Linden M. Differences in self-reported sleep complaints in elderly persons living the community who do or do not take sleep medication. J Clin Psychiatry 1998;59:137–144.

127. Gagliese L, Melzack R. Chronic pain in elderly people. Pain 1997;70:3–14.

128. Dao TT. Pain and gender. In: Lund JP, Lavigne GJ, Dubner R, Sessle BJ (eds). Orofacial Pain: From Basic Science to Clinical Management. Chicago: Quintessence, 2001:129–138.

129. Dao TT, LeResche L. Gender differences in pain. J Orofac Pain 2000;14:169–184.

130. Huang GJ, LeResche L, Critchlow CW, Martin MD, Dranghold MT. Risk factors for diagnostic subgroups of painful temporomandibular disorders (TMD). J Dent Res 2002;81:284–288.

131. Fillingim RB, Edwards RR. The association of hormone replacement therapy with experimental pain responses in postmenopausal women. Pain 2001;92:229–234.

132. Hatch JP, Rugh JD, Sakai S, Saunders MJ. Is use of exogenous estrogen associated with temporomandibular signs and symptoms? J Am Dent Assoc 2001;132: 319–326.

133. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A 2003;100:4867–4872.

134. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesis—Imaging a shared neuronal network. Science 2002;295:1737–1740.

135. Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F. Response expectancies in placebo analgesia and their clinical relevance. Pain 2001;93:77–84.

136. Zubieta JK, Smith YR, Bueller JA, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001;293:311–315.

137. Raber P, Devor M. Social variables affect phenotype in the neuroma model of neuropathic pain. Pain 2002;97: 139–150.

138. Zubieta J-K, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects muopioid neurotransmitter responses to a pain stressor. Science 2003;299: 1240–1243.

139. Seltzer Z, Dorfman R. Identifying genetic and environmental risk factors for chronic orofacial pain syndromes: Human models. J Orofac Pain 2004;18:311–317.

140. Ciancaglini R, Gherlone EF, Radaelli G. The relationship of bruxism with craniofacial pain and symptoms from the masticatory system in the adult population. J Oral Rehabil 2002;28:842–848.

141. Lobbezoo F, Lavigne GJ. Do bruxism and temporo-mandibular disorders have a cause and effect relation-ship? J Orofac Pain 1997;11:15–23.

142. Kato T, Thie N, Montplaisir J, Lavigne GJ. Bruxism and orofacial movements during sleep. Dent Clin North Am 2001;45:657–684.

143. Jänig W, Baron R. Complex regional pain syndrome: Mystery explained? Lancet Neurol 2003;2:687–697.